LLY Overview
Upcoming Projects (LLY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (LLY)
-
Understanding the impact of tofacitinib safety data that was released in January 2021 on JAK prescribing behavior in the U.S for RA and PsA.
Tickers: LLY, PFE, ABBV
Executed On: Aug 24, 2021 at 05:00 PM EDT -
Making sense of the about face for Aducanumab in Alzheimer's after Biogen reported full analysis of its Phase 3 trial suggests success at the higher dose.
Tickers: BIIB, LLY
Executed On: Nov 04, 2019 at 03:30 PM EST -
A detailed look at JNJ’s Esketamine Nasal spray in treatment resistant depression post FDA approval
Tickers: JNJ, LLY
Executed On: Mar 15, 2019 at 03:00 PM EDT -
Checking in on the Migraine landscape and impact oral and IV CGRPs might have on prescribing.
Tickers: BHVN, TEVA, LLY, AMGN
Executed On: Mar 15, 2019 at 01:00 PM EDT -
Examining the REWIND cardiovascular outcomes study for Trulicity (dulaglutide) with a Biostatistician
Ticker: LLY
Executed On: Sep 14, 2018 at 03:00 PM EDT -
A 4th View - Discussing the market potential of TYMLOS (Abaloparatide) after approval and positive ACTIVExtend results in osteoporosis.
Tickers: RDUS, MRK, AMGN, LLY
Executed On: Jan 30, 2018 at 01:00 PM EST -
Another Opinion - Discussing the market potential of TYMLOS (Abaloparatide) after approval and positive ACTIVExtend results in osteoporosis.
Tickers: RDUS, MRK, AMGN, LLY
Executed On: Jan 29, 2018 at 01:00 PM EST -
A Second Expert Opinion on Radius' (RDUS) Market Potential for Recently Approved Osteoporosis Drug TYMLOS (abaloparatide)
Tickers: RDUS, AMGN, LLY
Executed On: Aug 03, 2017 at 11:00 AM EDT -
Discussing the market potential of TYMLOS (Abaloparatide) after approval and positive ACTIVExtend results in osteoporosis.
Tickers: RDUS, MRK, AMGN, LLY
Executed On: Jun 23, 2017 at 11:30 AM EDT -
Alzheimer’s Disease: Market Opportunity & Major Phase 3 Treatments You Should Know
Tickers: LLY, AXON, BIIB
Executed On: Oct 19, 2016 at 12:00 PM EDT
Included with Membership -
Another Opinion: As Lipocine's LPCN-1021 nears its FDA PDUFA date for a deficiency or absence of endogenous testosterone ("hypogonadism") what will the agency say?
Tickers: LPCN, ABBV, ENDP, LLY, Clarus Therapeutics
Executed On: Jun 24, 2016 at 12:30 PM EDT -
A SECOND OPINION: As Lipocine's LPCN-1021 nears its FDA PDUFA date for a deficiency or absence of endogenous testosterone ("hypogonadism") what will the agency say?
Tickers: LPCN, LLY, Clarus Therapeutics, ENDP
Executed On: Jun 20, 2016 at 01:30 PM EDT -
As Lipocine's LPCN-1021 nears its FDA PDUFA date for a deficiency or absence of endogenous testosterone ("hypogonadism") what is the drug's potential?
Tickers: LPCN, ABBV, ENDP, LLY
Executed On: Jun 09, 2016 at 12:30 PM EDT -
Changing horses (endpoints) midstream (trial)? Discussing rationale for LLY's changing the EXPEDITION3 study from co-primary endpoints of change in cognition and function to just cognition.
Tickers: LLY, BIIB
Executed On: Mar 28, 2016 at 02:00 PM EDT -
The market potential of a likely soon to be approved Afrezza. Will this launch be different (better) than Exubera?
Tickers: MNKD, NVO, PFE, LLY
Executed On: Apr 15, 2014 at 01:00 PM EDT
Expired Projects (LLY)
-
Evaluating the Chances of Approval and Market Potential for Radius Health's (RDUS) Abaloparatide-SC for Postmenopausal Women with Osteoporosis
Tickers: RDUS, AMGN, LLY
Execute By: May 09, 2017 -
To see if we can get the specific DOJ requests to Pharma companies on drug pricing. These investigations have been confirmed in 10q filings.
Tickers: MRK, VRX, LLY
Execute By: Mar 04, 2016
Upcoming & Overdue Catalysts (LLY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (LLY)
-
Lilly's(LLY) Mirikizumab in Crohn's disease Phase 2 data due at DDW meeting 18-21 May, 2019
Ticker: LLY
Occurred on: May 21, 2019 -
Eli Lilly's (LLY) Galcanezumab Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache Data Presented
Ticker: LLY
Occurred on: May 15, 2018 -
Eagle Pharma's (EGRX) NDA for Liquid Version of Lilly's (LLY) Alimta Granted PDUFA Date of October 30th
Tickers: EGRX, LLY
Occurred on: Oct 27, 2017 -
FDA Decision Expected By April 5th for Merck's (MRK) Glargine (MK-1293) in Type 1 and Type 2 Diabetes
Tickers: MRK, SNY, LLY, NVO
Occurred on: Jul 20, 2017 -
FDA Decision on Baricitinib Expected April 19 2017
Tickers: INCY, LLY
Occurred on: Apr 14, 2017 -
Phase 3 MONARCH 2 Data Evaluating Abemaciclib in Patients with Relapsed/Refractory HR+/HER2- Breast Cancer
Ticker: LLY
Occurred on: Mar 20, 2017 -
Lilly's (LLY) Diabetes Med Trulicity Now Includes Label for Combination with Basal Insulin in Adults with Type 2 Diabetes
Ticker: LLY
Occurred on: Feb 08, 2017 -
U.S Court of Appeals Upholds Decision in Lilly's (LLY) Favor Regarding Patent for Alimta Vitamin Regimen
Ticker: LLY
Occurred on: Jan 12, 2017 -
The first FDA-approved follow-on insulin glargine treatment, BASAGLAR will be available in the U.S. starting on December 15, 2016
Ticker: LLY
Occurred on: Dec 15, 2016 -
Lilly (LLY) Presents NeoMONARCH Phase 2 Data On Abemaciclib In Early-Stage Breast Cancer
Ticker: LLY
Occurred on: Dec 08, 2016 -
FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
Ticker: LLY
Occurred on: Dec 02, 2016 -
Solanezumab Phase III Alzheimer's data (EXPEDITION-3) expected year end 2016
Tickers: BIIB, LLY
Occurred on: Nov 23, 2016 -
Lilly's (LLY) Lartruvo Approved by FDA by Soft Tissue Sarcoma
Ticker: LLY
Occurred on: Oct 19, 2016 -
Decision on Lilly's (LLY) Olaratumab in Soft Tissue Sarcoma Expected From European Medicines Agency By End of November
Ticker: LLY
Occurred on: Oct 19, 2016 -
Lilly's (LLY) Olaratumab + Doxorubicin in Soft Tissue Sarcoma Recommended for Approval by European Ad Comm
Ticker: LLY
Occurred on: Sep 16, 2016 -
Lilly (LLY) and Boehringer Ingelheim's Glyxambi Recommended for Approval by European Ad Comm for Type 2 Diabetes
Tickers: LLY, Boehringer Ingelheim
Occurred on: Sep 16, 2016 -
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Tickers: AZN, LLY
Occurred on: Aug 22, 2016 -
Data for Phase 2 MONARCH 1 Trial of Abemaciclib Expected mid-2016
Ticker: LLY
Occurred on: Jun 03, 2016 -
FDA Rolling Submission of Olaratumab Expected to be Complete By End of H1 of 2016
Ticker: LLY
Occurred on: May 04, 2016 -
FDA Grants Priority Review for Lilly's Olaratumab, an Investigational Medicine for Advanced Soft Tissue Sarcoma
Ticker: LLY
Occurred on: May 04, 2016 -
Eli Lilly and Company and AstraZeneca Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer's Disease
Tickers: LLY, AZN
Occurred on: Apr 08, 2016 -
Lilly to Present Data from Phase 3 Studies on Ixekizumab in Psoriasis and Psoriatic Arthritis
Ticker: LLY
Occurred on: Apr 07, 2016 -
Phase 3 Studies of Tanezumab for Chronic Pain Resume After Partial Clinical Hold
Tickers: PFE, LLY
Occurred on: Mar 23, 2016 -
Lilly's Taltz (ixekizumab) Receives U.S. FDA Approval for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Mar 22, 2016 -
Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Mar 07, 2016 -
Lilly Receives Positive CHMP Opinion for Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis
Ticker: LLY
Occurred on: Feb 26, 2016 -
UK Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit
Ticker: LLY
Occurred on: Feb 12, 2016 -
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly to develop drugs based on ENHANZE
Tickers: HALO, LLY
Occurred on: Dec 21, 2015 -
Lilly (LLY) Announces Positive Phase 3 SPIRIT-P1 Data Evaluating Ixekizumab in Patients With Psoriatic Arthritis
Tickers: LLY, ABBV
Occurred on: Nov 08, 2015 -
Merck (MRK) Receives Inquiries Over Certain Aspects of Drug Pricing
Tickers: MRK, VRX, LLY, Turing
Occurred on: Oct 19, 2015 -
Lilly (LLY) Receives Inquiries Over Certain Aspects of Drug Pricing (Date is an estimate for "September")
Tickers: LLY, VRX, MRK
Occurred on: Sep 15, 2015 -
LLY Expects Alzheimer's Drug Solanezumab EXPEDITION-2 Data Readout Early 2014
Ticker: LLY
Occurred on: Jan 23, 2014 -
Top-Line Results on Solanezumab Phase 3 Clinical Trial in Patients with Alzheimer's Disease
Ticker: LLY
Occurred on: Apr 25, 2012
Strategic Initiatives (LLY)
-
Lilly (LLY) Completes Acquisition of Dermira (DERM)
Tickers: LLY, DERM
Announcement Date: Feb 20, 2020 -
Eli Lilly to Acquire AurKa Pharma
Ticker: LLY
Announcement Date: May 14, 2018 -
Juno Therapeutics Signs Licensing Agreement with Lilly to Advance Its BCMA-Directed Engineered T Cell Program in Multiple Myeloma with Gamma Secretase Inhibition
Tickers: JUNO, LLY
Announcement Date: Dec 06, 2017 -
Eli Lilly (LLY) Acquires CoLucid Pharmaceuticals (CLCD) for ~$960MM Cash
Ticker: LLY
Announcement Date: Jan 18, 2017 -
Lilly (LLY) and Merck (MRK) Expand Existing Oncology Collaboration, Agree to Evaluating Lartruvo + Keytruda in Advanced/Metastatic Soft Tissue Sarcoma
Tickers: LLY, MRK
Announcement Date: Jan 11, 2017 -
Lilly's (LLY) Elanco Unit Acquires Boehringer Ingelheim's Rabies Vaccine Portfolio for $885M
Tickers: LLY, Boehringer Ingelheim, Vetmedica, Elanco
Announcement Date: Oct 05, 2016 -
Lilly And Boehringer Ingelheim Announce Clinical Trial Collaboration In Metastatic Breast Cancer
Tickers: LLY, Boehringer Ingelheim
Announcement Date: Jul 13, 2016 -
Lilly and Roche Diagnostics to Collaborate on Alzheimer's Disease Adjunct Diagnostic Tool
Tickers: LLY, RHHBY
Announcement Date: Jan 27, 2016
